Literature DB >> 20516275

Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model.

G L Drusano1, Christine Fregeau, Weiguo Liu, D L Brown, Arnold Louie.   

Abstract

We wished to delineate granulocytes' impact on the clearance of different bacterial burdens of Pseudomonas aeruginosa and Staphylococcus aureus in a granulocyte-replete mouse thigh infection model. A mouse thigh model was employed. Bacterial challenges from 10(5) to 3 × 10(7) CFU (S. aureus) and from 3 × 10(4) to 3 × 10(8) CFU (P. aeruginosa) were injected into murine posterior thighs. Organism quantitation was at baseline, 2 h (Pseudomonas only), and 24 h. A Michaelis-Menten population model was fit to the data for each organism. Breakpoints for microbial containment by granulocytes were identified. Bacterial burdens exceeding that breakpoint value resulted in organism multiplication. The Michaelis-Menten model fit the data well. For P. aeruginosa, the observed-predicted plot had a regression equation that explained over 98% of the variance (P ≪ 0.001). For S. aureus, this relationship explained greater than 94% of the variance (P ≪ 0.001). Maximal growth rate constants, maximal population burdens, and the bacterial loads at which granulocytes killed if half-saturated were not different. The kill rate constant for P. aeruginosa was almost 10 times that of S. aureus. Bacterial kill by granulocytes is saturable. No difference between saturation points of different isolates was seen. A higher bacterial burden means an increasing reliance on chemotherapy to drive bacterial clearance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20516275      PMCID: PMC2944594          DOI: 10.1128/AAC.00133-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Kinetics of phagocytosis of Staphylococcus aureus and Escherichia coli by human granulocytes.

Authors:  P C Leijh; M T van den Barselaar; T L van Zwet; I Dubbeldeman-Rempt; R van Furth
Journal:  Immunology       Date:  1979-06       Impact factor: 7.397

2.  Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

3.  Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis.

Authors:  William W Hope; George L Drusano; Caroline B Moore; Andrew Sharp; Arnold Louie; Thomas J Walsh; David W Denning; Peter A Warn
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

Review 4.  Use of pharmacokinetics and pharmacodynamics in a failure analysis of community-acquired pneumonia: implications for future clinical trial study design.

Authors:  Paul G Ambrose
Journal:  Clin Infect Dis       Date:  2008-12-01       Impact factor: 9.079

Review 5.  Historical and regulatory perspectives on the treatment effect of antibacterial drugs for community-acquired pneumonia.

Authors:  M Singer; S Nambiar; T Valappil; K Higgins; S Gitterman
Journal:  Clin Infect Dis       Date:  2008-12-01       Impact factor: 9.079

6.  In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.

Authors:  W A Craig; D R Andes
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

7.  Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.

Authors:  Keith A Rodvold; David P Nicolau; Thomas P Lodise; Mohammed Khashab; Gary J Noel; James B Kahn; Mark Gotfried; Sara A Murray; Susan Nicholson; Somvadee Laohavaleeson; Pamela R Tessier; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

8.  High pneumococcal DNA loads are associated with mortality in Malawian children with invasive pneumococcal disease.

Authors:  Enitan D Carrol; Malcolm Guiver; Standwell Nkhoma; Limangeni A Mankhambo; John Marsh; Paul Balmer; Daniel L Banda; Graham Jeffers; Sarah A White; Elizabeth M Molyneux; Malcolm E Molyneux; Rosalind L Smyth; C Anthony Hart
Journal:  Pediatr Infect Dis J       Date:  2007-05       Impact factor: 2.129

9.  Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets.

Authors:  Arnold Louie; Christine Fregeau; Weiguo Liu; Robert Kulawy; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

10.  Influence of subinhibitory concentrations of penicillin, cephalothin, and clindamycin on Staphylococcus aureus growth in human phagocytic cells.

Authors:  G R Elliott; P K Peterson; H A Verbrugh; M R Freiberg; J R Hoidal; P G Quie
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

View more
  30 in total

Review 1.  Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1.

Authors:  G L Drusano; Arnold Louie; Alasdair MacGowan; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

2.  Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.

Authors:  Phillip J Bergen; Jürgen B Bulitta; Carl M J Kirkpatrick; Kate E Rogers; Megan J McGregor; Steven C Wallis; David L Paterson; Roger L Nation; Jeffrey Lipman; Jason A Roberts; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

3.  Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model.

Authors:  George Louis Drusano; Weiguo Liu; Steven Fikes; Ryan Cirz; Nichole Robbins; Stephanie Kurhanewicz; Jaime Rodriquez; David Brown; Dodge Baluya; Arnold Louie
Journal:  J Infect Dis       Date:  2014-04-22       Impact factor: 5.226

Review 4.  What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.

Authors:  Chandra Datta Sumi; Aaron J Heffernan; Jeffrey Lipman; Jason A Roberts; Fekade B Sime
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

5.  Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic In Vitro Hollow-Fiber Infection Model.

Authors:  Aaron J Heffernan; Fekade B Sime; Derek S Sarovich; Michael Neely; Yarmarly Guerra-Valero; Saiyuri Naicker; Kyra Cottrell; Patrick Harris; Katherine T Andrews; David Ellwood; Steven C Wallis; Jeffrey Lipman; Keith Grimwood; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 6.  The immune response and antibacterial therapy.

Authors:  Olachi Anuforom; Graham R Wallace; Laura V Piddock
Journal:  Med Microbiol Immunol       Date:  2014-09-05       Impact factor: 3.402

Review 7.  Translational PK/PD of anti-infective therapeutics.

Authors:  Chetan Rathi; Richard E Lee; Bernd Meibohm
Journal:  Drug Discov Today Technol       Date:  2016-10-28

8.  Evaluating a tylosin dosage regimen for treatment of Staphylococcus delphini infection in mink (Neovison vison): a pharmacokinetic-pharmacodynamic approach.

Authors:  Amir Atabak Ronaghinia; Julie Melsted Birch; Henrik Lauritz Frandsen; Pierre-Louis Toutain; Peter Damborg; Tina Struve
Journal:  Vet Res       Date:  2021-02-27       Impact factor: 3.683

Review 9.  Is it time to move away from polymyxins?: evidence and alternatives.

Authors:  Rajeev Soman; Yamuna Devi Bakthavatchalam; Abinaya Nadarajan; Hariharan Triplicane Dwarakanathan; Ramasubramanian Venkatasubramanian; Balaji Veeraraghavan
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-10-02       Impact factor: 3.267

10.  Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design.

Authors:  Cornelia B Landersdorfer; Neang S Ly; Hongmei Xu; Brian T Tsuji; Jürgen B Bulitta
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.